

AMENDMENTIn the Claims:

Please cancel Claims 35-96 without prejudice as being directed to an unelected group.

Please amend the remaining claims as follows.

SUB  
C  
1  
a

101.(Amended) The pharmaceutical composition of Claim 97, wherein the medicant is a therapeutic cytotoxic agent, DNA expression vector, viral vector, protein, oligonucleotide, nucleotide analog, antimicrobial agent, interferon, cytokine, cytokine agonist, cytokine antagonist, immunotoxin, immunosuppressant, boron compound, monoclonal antibody, adrenergic agent, anticonvulsant, ischemia-protective agent, anti-trauma agent, [anticancer chemotherapeutic agent,] or diagnostic agent.

2  
8  
E14

104.(Amended) The pharmaceutical composition of Claim 97, wherein the medicant is a N-methyl-D-aspartate (NMDA) receptor antagonist, antibiotic, interleukin-2; or transforming growth factor- $\beta$  [, cisplatin, carboplatin, tumor necrosis factor- $\alpha$  , methotrexate, 5-fluorouracil, amphotericin, daunorubicin, doxorubicin, vincristine, vinblastine, busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid].

3  
SUB  
C  
7

108.(Amended) A kit for enhancing the delivery of a medicant to an abnormal brain region [and/or to a malignant tumor], comprising:  
a potassium channel agonist, other than bradykinin or a bradykinin analog; and  
instructions for using the potassium channel agonist for enhancing the delivery of a medicant to an abnormal brain region [or to a malignant tumor].

Pending Claims

Prior to the above amendments, Claims 1-109 are pending. Claims 1-34 are directed to a method of delivering a medicant to an abnormal brain region in a mammalian subject. Claims 35-67 relate to a method of delivering a medicant to a malignant tumor in a mammalian